Main Article Content

Abstract

Posaconazole is a triazole antifungal drug and used for the treatment of infections caused by fungai. During the process development of posaconazole, the process related impurity deshydroxy posaconazole was identified as a critical impurity along with the final active pharmaceutical ingredient. The present work describes the synthesis and characterization of this deshydroxy posaconazole.

Keywords

ICH Antifungal Impurity Posaconazole

Article Details

How to Cite
Kumar Kannasani, R., Reddy Battula, S., Venkata Babu, V., Kumar Bandaru, D., Mula, S., & Sekhar Saketi, R. (2016). Synthesis and Characterization of Deshydroxy Posaconazole. Asian Journal of Organic & Medicinal Chemistry, 1(3), 87–90. https://doi.org/10.14233/ajomc.2016.AJOMC-P26

References

  1. International Conference on Harmonization (ICH) Guidelines, Q3A (R) Impurities in New Drug Substances, February (2002).
  2. International Conference on Harmonization (ICH) Guidelines, Impurities in New Drug Products, Q3B (R1) (2006).
  3. Posanol (Posaconazole) Product Monograph, Merck Canada Inc. (2014).
  4. Noxafil: EPAR—European Medicines Agency-Europa Annex I Summary of Product Characteristics.
  5. X. Li, N. Brown and A.S. Chau, J. Antimicrob. Chemother., 53, 74 (2003); http://dx.doi.org/10.1093/jac/dkh027.
  6. G.M. Keating, Drugs, 65, 1553 (2005); http://dx.doi.org/10.2165/00003495-200565110-00007.
  7. D.V. Prasad, R.V. Reddy and P. Aparna, Am. J. Anal. Chem., 6, 965 (2015); http://dx.doi.org/10.4236/ajac.2015.612092.
  8. M. Gharpure, V. Krishna, S.R. Sanikommu, G. Chaudhari, J. Verdia and M.A. Khan, Process for Preparation of Posaconazole and Crystalline Polymorphic Form V of Posaconazole, Patent WO2011158248 A2 (2011).